BSEM
Price
$15.90
Change
+$0.18 (+1.15%)
Updated
Jan 17 closing price
Capitalization
259.49M
78 days until earnings call
VIRX
Price
$0.17
Change
-$0.01 (-5.56%)
Updated
Jan 17 closing price
Capitalization
6.71M
58 days until earnings call
Ad is loading...

BSEM vs VIRX

Header iconBSEM vs VIRX Comparison
Open Charts BSEM vs VIRXBanner chart's image
BioStem Technologies
Price$15.90
Change+$0.18 (+1.15%)
Volume$53.99K
Capitalization259.49M
Viracta Therapeutics
Price$0.17
Change-$0.01 (-5.56%)
Volume$1.4M
Capitalization6.71M
BSEM vs VIRX Comparison Chart
Loading...
BSEM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VIRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BSEM vs. VIRX commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BSEM is a Hold and VIRX is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (BSEM: $15.90 vs. VIRX: $0.17)
Brand notoriety: BSEM and VIRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BSEM: 74% vs. VIRX: 48%
Market capitalization -- BSEM: $259.49M vs. VIRX: $6.71M
BSEM [@Biotechnology] is valued at $259.49M. VIRX’s [@Biotechnology] market capitalization is $6.71M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BSEM’s FA Score shows that 2 FA rating(s) are green whileVIRX’s FA Score has 1 green FA rating(s).

  • BSEM’s FA Score: 2 green, 3 red.
  • VIRX’s FA Score: 1 green, 4 red.
According to our system of comparison, BSEM is a better buy in the long-term than VIRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BSEM’s TA Score shows that 4 TA indicator(s) are bullish while VIRX’s TA Score has 4 bullish TA indicator(s).

  • BSEM’s TA Score: 4 bullish, 3 bearish.
  • VIRX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, BSEM is a better buy in the short-term than VIRX.

Price Growth

BSEM (@Biotechnology) experienced а +6.00% price change this week, while VIRX (@Biotechnology) price change was -9.19% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

BSEM is expected to report earnings on May 20, 2025.

VIRX is expected to report earnings on May 07, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BSEM($259M) has a higher market cap than VIRX($6.71M). BSEM YTD gains are higher at: 14.884 vs. VIRX (4.972). BSEM has higher annual earnings (EBITDA): -8.62M vs. VIRX (-39.67M). VIRX has more cash in the bank: 21.1M vs. BSEM (110K). BSEM has less debt than VIRX: BSEM (6.02M) vs VIRX (16.9M). BSEM has higher revenues than VIRX: BSEM (6.04M) vs VIRX (0).
BSEMVIRXBSEM / VIRX
Capitalization259M6.71M3,858%
EBITDA-8.62M-39.67M22%
Gain YTD14.8844.972299%
P/E RatioN/AN/A-
Revenue6.04M0-
Total Cash110K21.1M1%
Total Debt6.02M16.9M36%
FUNDAMENTALS RATINGS
BSEM vs VIRX: Fundamental Ratings
BSEM
VIRX
OUTLOOK RATING
1..100
5071
VALUATION
overvalued / fair valued / undervalued
1..100
4
Undervalued
69
Overvalued
PROFIT vs RISK RATING
1..100
31100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
3794
P/E GROWTH RATING
1..100
10013
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BSEM's Valuation (4) in the null industry is somewhat better than the same rating for VIRX (69) in the Biotechnology industry. This means that BSEM’s stock grew somewhat faster than VIRX’s over the last 12 months.

BSEM's Profit vs Risk Rating (31) in the null industry is significantly better than the same rating for VIRX (100) in the Biotechnology industry. This means that BSEM’s stock grew significantly faster than VIRX’s over the last 12 months.

BSEM's SMR Rating (100) in the null industry is in the same range as VIRX (100) in the Biotechnology industry. This means that BSEM’s stock grew similarly to VIRX’s over the last 12 months.

BSEM's Price Growth Rating (37) in the null industry is somewhat better than the same rating for VIRX (94) in the Biotechnology industry. This means that BSEM’s stock grew somewhat faster than VIRX’s over the last 12 months.

VIRX's P/E Growth Rating (13) in the Biotechnology industry is significantly better than the same rating for BSEM (100) in the null industry. This means that VIRX’s stock grew significantly faster than BSEM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BSEMVIRX
RSI
ODDS (%)
N/A
Bearish Trend 12 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 12 days ago
90%
Bullish Trend 12 days ago
89%
Momentum
ODDS (%)
Bullish Trend 12 days ago
81%
Bearish Trend 12 days ago
90%
MACD
ODDS (%)
Bullish Trend 12 days ago
73%
Bearish Trend 12 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 12 days ago
74%
Bullish Trend 12 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 12 days ago
76%
Bullish Trend 12 days ago
86%
Advances
ODDS (%)
Bullish Trend 12 days ago
80%
Bullish Trend 17 days ago
87%
Declines
ODDS (%)
Bearish Trend 21 days ago
78%
Bearish Trend 12 days ago
90%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bullish Trend 12 days ago
80%
Bullish Trend 12 days ago
80%
View a ticker or compare two or three
Ad is loading...
BSEM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VIRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SGMT4.390.12
+2.81%
Sagimet Biosciences
PACK6.370.05
+0.79%
Ranpak Holdings Corp
CDP29.57-0.21
-0.71%
COPT Defense Properties
PATH13.02-0.33
-2.47%
UiPath
ADIL0.96-0.08
-7.69%
Adial Pharmaceuticals

BSEM and

Correlation & Price change

A.I.dvisor tells us that BSEM and VTYX have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BSEM and VTYX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BSEM
1D Price
Change %
BSEM100%
+1.15%
VTYX - BSEM
22%
Poorly correlated
+6.88%
TSVT - BSEM
20%
Poorly correlated
+6.97%
ABSI - BSEM
20%
Poorly correlated
+3.57%
AURA - BSEM
20%
Poorly correlated
+1.30%
VIRX - BSEM
20%
Poorly correlated
-6.06%
More

VIRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, VIRX has been loosely correlated with MDGL. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if VIRX jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VIRX
1D Price
Change %
VIRX100%
-6.06%
MDGL - VIRX
38%
Loosely correlated
+7.64%
CHRS - VIRX
34%
Loosely correlated
-2.11%
AXON - VIRX
30%
Poorly correlated
+1.37%
CYTK - VIRX
30%
Poorly correlated
-2.66%
CDTX - VIRX
27%
Poorly correlated
+2.12%
More